Related Experiment Videos
New developments in immunosuppressive therapy in renal transplantation
Sita Gourishankar1, Penny Turner, Philip Halloran
1Division of Nephrology and Immunology, University of Alberta, Edmonton, Canada. gsita@hotmail.com
Expert Opinion on Biological Therapy
|June 25, 2002
Summary
New immunosuppressive therapies enhance renal transplant outcomes by reducing rejection and improving graft function. Focus is shifting towards minimizing side effects and preventing long-term graft loss.
Area of Science:
- Nephrology
- Immunology
- Transplantation Medicine
Background:
- Renal transplant outcomes have improved due to advancements in immunosuppressive agents and protocols.
- Key therapies include calcineurin inhibitors, mTOR inhibitors, mycophenolate mofetil, and various antibody treatments.
Purpose of the Study:
- To review major changes in immunosuppressive therapy combinations for renal transplant recipients.
- To discuss novel agents and evolving treatment goals, including steroid and calcineurin inhibitor minimization.
- To highlight the shift towards improving graft function and reducing adverse effects.
Main Methods:
- Review of current and emerging immunosuppressive agents and protocols.
- Analysis of therapeutic combinations: calcineurin inhibitors, mTOR inhibitors, mycophenolate mofetil, and antibody therapies.
- Discussion of novel agents targeting specific immunological pathways.
Main Results:
- Improved renal allograft survival and function through optimized immunosuppression.
- Reduced risk of acute rejection with current therapeutic strategies.
- Emerging focus on minimizing drug toxicity, hypertension, and hyperlipidemia.
Conclusions:
- Current immunosuppressive protocols enhance renal transplant success by lowering rejection rates and improving graft longevity.
- Future strategies aim to optimize graft function, reduce adverse effects, and prevent late graft deterioration.
- Novel immunosuppressive agents show promise but require further clinical validation.